NCT00920816 2022-05-06Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell CancerPfizerPhase 3 Completed492 enrolled 17 charts
NCT00678392 2019-01-09Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell CancerPfizerPhase 3 Completed723 enrolled 15 charts
NCT00492258 2013-08-12Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerNational Cancer Institute (NCI)Phase 3 Completed1,656 enrolled